Gotham Asset Management LLC Has $7.21 Million Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Gotham Asset Management LLC increased its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 21.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 21,949 shares of the medical research company's stock after acquiring an additional 3,805 shares during the quarter. Gotham Asset Management LLC owned about 0.08% of Bio-Rad Laboratories worth $7,210,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Venturi Wealth Management LLC increased its holdings in shares of Bio-Rad Laboratories by 2,175.0% during the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock worth $30,000 after acquiring an additional 87 shares during the last quarter. GeoWealth Management LLC boosted its stake in Bio-Rad Laboratories by 342.9% in the 4th quarter. GeoWealth Management LLC now owns 93 shares of the medical research company's stock valued at $31,000 after purchasing an additional 72 shares during the period. Picton Mahoney Asset Management boosted its stake in Bio-Rad Laboratories by 55.6% in the 4th quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock valued at $32,000 after purchasing an additional 35 shares during the period. Asset Planning Inc bought a new stake in Bio-Rad Laboratories in the 4th quarter valued at $33,000. Finally, UMB Bank n.a. boosted its stake in Bio-Rad Laboratories by 41.6% in the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock valued at $36,000 after purchasing an additional 32 shares during the period. 65.24% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. UBS Group reduced their price target on Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Citigroup reduced their price target on Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Wells Fargo & Company reduced their price target on Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating for the company in a research note on Thursday, April 17th. StockNews.com downgraded Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Monday, February 17th. Finally, Royal Bank of Canada cut their target price on Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, Bio-Rad Laboratories presently has a consensus rating of "Moderate Buy" and a consensus price target of $327.40.

Bio-Rad Laboratories Price Performance

BIO traded up $5.26 on Friday, reaching $248.45. The stock had a trading volume of 254,950 shares, compared to its average volume of 321,515. Bio-Rad Laboratories, Inc. has a fifty-two week low of $215.38 and a fifty-two week high of $387.99. The firm has a 50-day moving average of $243.51 and a 200-day moving average of $299.31. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $6.96 billion, a price-to-earnings ratio of -3.82 and a beta of 1.00.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical research company reported $2.54 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.73 by $0.81. The business had revenue of $585.40 million during the quarter, compared to analysts' expectations of $573.01 million. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. The business's revenue for the quarter was down 4.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.30 EPS. As a group, sell-side analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.